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Abstract: We demonstrate the ability to non-invasively and quantitatively 
image lymphatic architecture and contractile function using dynamic near-
infrared (NIR) fluorescence imaging with injection of indocyanine green in 
normal and transgenic mice. Unlike normal mice, which showed well 
defined lymphatic drainage patterns and orthograde propagation of 
contraction waves, we observed tortuous and mispatterned lymphatic 
vessels and persistent retrograde lymph flow in mice with deficiency in 
Prox1, a transcription factor essential for lymphatic vascular development. 
NIR fluorescence imaging provides a method for quantifying lymphatic 
function for future studies designed to discern differences in lymphatic 
function in murine models of human lymphatic disease. 
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1. Introduction 
The lymphatic system plays an important yet poorly understood role in cancer metastasis, 
immune surveillance, lipid absorption, and fluid homeostasis. Impaired lymphatic function 
has been implicated in many pathophysiological conditions, including asthma, diabetes, 
edema, and obesity [1–3]. The potential impact of lymphatic dysfunction has spawned 
vigorous research programs in the study of molecular mechanisms of developmental and adult 
lymphangiogenesis, the process by which new lymph vessels are formed [1]. Yet, although 
the lymphatics represent an important component of the microcirculation system, there is little 
understanding of its architecture and function, due presumably to the lack of imaging 
techniques to non-invasively image lymphatic vessels. 
In mouse models of human disease, lymphatic architecture and function has been 
examined using traditional imaging techniques with injection of Evans blue dye (EBD) or 
dextran bound with common fluorescent dyes that excite in the visible wavelength range [4–
6]. All of these studies either employed an invasive, acute preparation that can impact 
lymphatic function or non-invasive imaging of the lymphatics in the ear or tail where visual 
observations can be directly made. In man, lymphatic function and architecture is currently 
imaged with lymphoscintigraphy, a nuclear imaging technique which lacks the temporal and 
spatial resolution required to assess dynamic, lymphatic contractile function. 
Recently, we developed non-invasive, near-infrared (NIR) fluorescence imaging of the 
lymphatics with intradermal (i.d.) injection of indocyanine green (ICG) [7–9], a dye that 
associates with albumin and has been used clinically in retinopathy and hepatic studies on the 
basis of its dark green color [10,11]. Upon employing NIR excitation at 780 nm to collect 
fluorescence at 830 nm, tissue penetration is enhanced and background owing to 
autofluorescence is minimized [12]. Due to its association with albumin, we have found that 
ICG is preferentially and rapidly taken up by the initial lymphatics when administered 
intradermally. Using non-invasive dynamic NIR fluorescence imaging, we have reported for 
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lymphatic architecture and contractile function in tumor-bearing mice with lymph node (LN) 
metastasis [9]. We have also used NIR fluorescence imaging of lymphatic trafficking in 
patients with breast cancer, head and neck cancer, and lymphedema [13–16]. Although 
hairless immunodeficient nude mice are useful for the study of fluorescence imaging of 
propulsive lymph flow because their lack of hair prevents interference with NIR fluorescence 
imaging, in vivo studies must be performed in immunocompetent mice to match the strain 
backgrounds of transgenic mice that are engineered to mimic human lymphovascular 
disorders. In this study, we show lymphatic contractile function in C57BL/6 mice, the 
background of most transgenic mice. 
A number of genetic mutations have been associated with the congenital and hereditary 
human lymphovascular disorder of lymphedema, a broadly classified disease in which the 
lymphatics fail to transport excess fluid and macromolecules that have filtered from the blood 
vasculature causing irreversible edema and a sequaele of inflammatory responses. There is no 
cure for lymphedema. While several transgenic mouse models of lymphatic disorders have 
been developed, non-invasive characterization of lymphatic contractile function has not been 
performed in any of these models. PROX1 is a gene that encodes for a transcription factor 
unique to the lymphatics and essential for developmental lymphangiogenesis [17]. Deletion of 
the PROX1 gene is embryonically lethal in mice, whereas heterozygous PROX1 (PROX1+/) 
mice survive [3]. However, these mice are obese compared with their wild-type counterparts 
and indirect, invasive imaging with injection of EBD showed abnormal lymphatic drainage 
[3]. Yet to date lymphatic contractile function in PROX1+/ mice has not been assessed in 
vivo. Herein, we present NIR fluorescence imaging of the lymphatics of athymic nude, 
C57BL/6, and PROX1+/ mice. The objective of this study is to show that non-invasive, 
dynamic NIR fluorescence imaging is sensitive enough to phenotype transgenic animal 
models of lymphatic disorders. This work provides an example of transgenic mouse imaging 
to phenotype lymphovascular disorders that might be linked to hereditary lymphatic disorders 
in humans. 
2. Materials and methods 
2.1. Animals 
Athymic nude and C57BL/6 mice (Charles River Laboratories, Inc., Wilmington, MA) and 
PROX1+/ mice (provided by Dr. Guillermo Oliver, St. Jude’s Hospital, Memphis, 
Tennessee) were maintained in a pathogen-free mouse colony at the Frensley Center of 
Imaging Research at Baylor College of Medicine and at the Brown Institute of Molecular 
Medicine, University of Texas Health Science Center at Houston (UTHSC-H), which are 
accredited by the Association for the Assessment and Accreditation of Laboratory Animal 
Care. Imaging studies of C57BL/6 mice were conducted at UTHSC-H. All animal 
experimentation was performed after approval by the Institutional Animal Care and Use 
Committee. 
2.2. In vivo NIR lymphatic imaging 
In order to prevent fur from interfering with the fluorescent signal, C57BL/6 and PROX1+/ 
mice were clipped and a depilatory agent (Nair, Church & Dwight Co., Inc., Princeton, NJ) 
was used to remove residual hair 24 hr before fluorescence imaging. At the time of imaging, 
animals were placed under isofluorane anesthesia and maintained at 37 °C. A volume of 10 to 
40  μL of 645 µM of ICG (IC-Green, Akorn, Inc., Buffalo Grove, IL) or 10 μl of EBD 
(5mg/ml; Sigma, St. Louis, MO) reconstituted in USP standard 0.9% Sodium Chloride 
(Hospira, Inc., Lake Forest, IL) was injected intradermally into the base of each mouse tail 
with 31-gauge needles (BD Ultra-Fine
TM II Short Needle, Becton and Dickinson Medical, 
Franklin, NJ). Fluorescence images were acquired immediately after injection and for up to 30 
min following injection. 
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illuminated with 785 nm light from a laser diode (85 mA, 785 nm, model Sanyo DL7140-201, 
Newton, NJ) using a convex lens and diffuser to create a uniform excitation field. Filter sets 
used in this study included an interference filter (Image quality, model 830.0-2.0, Andover 
Corp., Salem, NH) to transmit fluorescent emission light and a holographic filter (model 
HNPF-785.0-2.0, Kaiser Optical Systems, Inc., Ann Arbor, MI) to reject reflected excitation 
light. The fluorescence images were captured by an electron-multiplying charge-coupled 
device (EMCCD) camera (PhotonMax 512B, Princeton Instruments, Tucson, AZ) with 100 or 
200 ms integration time for dynamic imaging and 800 ms for static imaging. To acquire 
white-light images for registration purposes, the optical filters were removed and a low-power 
lamp illuminated the animal. Image acquisition was accomplished by V++ software (Digital 
Optics, Aukland, New Zealand). To achieve a greater magnification, a macrolens (Leica Z16 
APO, Leica Microsystems, Inc., Bannockburn, IL) was placed on the EMCCD camera and 
holographic and bandpass filters were attached to the macrolens for fluorescence imaging. 
At the end of the imaging session, intravital fluorescence imaging was performed. An arc-
shaped midway incision was made in the abdominal skin from the inguinal to the axillary 
regions. The subcutaneous (s.c.) connective tissue was separated to free the skin flap without 
injuring the lymphatic vessels. The inguinal LN (ILN) and the axillary LN (ALN) were 
exposed from the inner side. After mice were placed in a supine position and the skin flap was 
carefully spread and fixed, intravital fluorescence imaging was conducted. For intravital color 
imaging, EBD was intradermally injected several millimeters distal to the site of the ICG 
injection. Color images were acquired using a stereomicroscope (MZ16 A, Leica 
Microsystems, Inc., Bannockburn, IL). 
2.3. Data analysis 
Matlab (The MathWorks, Inc., Natick, MA) and ImageJ (National Institutes of Health, 
Washington, DC) were used to analyze the fluorescence imaging data in the following 
manner. Sequential frames of fluorescence images affected by respiratory motion were 
excluded for the subsequent data analysis presented herein. Fixed regions of interest (ROIs) of 
equivalent areas were selected along the entire length of the fluorescent lymphatic vessels on 
fluorescence images as was similarly done for human lymphatic imaging [14,18]. The 
averaged fluorescent intensity within each selected ROI was plotted as a function of imaging 
time and length of the lymphatic vessels. Thus, a three-dimensional plot of fluorescent 
intensity as a function of time and distance was generated to assess the propagation velocity 
and the frequency of an ICG-laden lymph fluid “packet” propelled along the lymphatic 
vessels. From the time between disappearance of a lymph “packet” from a selected ROI and 
its appearance at another ROI a known distance away from the first, the propagation velocity 
was directly computed for each “packet.” By assessing the number of fluorescent pulses or 
“packets” arriving at a ROI, the contractile frequency was computed. 
3. Results and discussion 
Figure 1A shows an example of a fluorescent image frame from Media 1 in the ventrolateral 
view of a nude mouse displaying the lymphatic trafficking of ICG from the base of the tail, 
where ICG was intradermally injected, to the ILN, and subsequently to the ALN. The 
lymphatic vessels on the lower left ventral side and contralateral regions were also visualized. 
In order to determine lymphatic contractile function, a series of 66 ROIs were selected along 
the entire fluorescent collecting lymphatic vessel as shown in Fig. 1B. 
Figure 1C shows a generated, three-dimensional (3-D) spatial-temporal map of fluorescent 
intensity as a function of time and length, showing coordinated propagation of 19 contraction 
waves. The frequency of propagating contractions averaged 6.24/min. We also observed 
lower frequency of contractions (1.33/min) in inguinal afferent lymphatic vessels and 
asynchronous propulsion of ICG between afferent (pre-nodal) and efferent (post-nodal) 
collecting lymphatic vessels. The different lymph pump activities between the afferent and  
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Fig. 1. NIR fluorescence image (A, Media 1) of the lymphatics in a nude mouse and 
quantification of lymphatic contractile function after selection of 66 ROIs along the lymphatic 
vessel (B). A 3-D plot of fluorescent intensity as a function of time and distance (C) shows the 
propagation of the fluorescent packet along the lymphatic vessel (arrows). Plot of fluorescent 
intensity profiles for two ROIs (D) from which the distance between the ROIs and the time are 
obtained. 
efferent lymphatic vessels in the LN were observed previously in isolated lymphatic vessels 
[19,20]. 
To quantify the apparent propagation velocity of contraction waves, two ROIs were 
selected over the lymphatic vessel. As an example, Fig. 1D shows fluorescent intensity as a 
function of time for 10 s for ROI 1 and ROI 66 (i.e., the first and the last ROI as shown in Fig. 
1C, respectively). The transit time was determined by indentifying the multiple fluorescent 
intensity peaks in both ROIs and was found to average 6.78 ± 2 s during 19 propagating 
contractions. Since the distance between two ROIs was 1.8304 cm, the averaged apparent 
propagation velocity was calculated to be 2.96 ± 1.02 mm/s. Unlike the contractile frequency, 
there was no apparent difference in propagation velocities between afferent and efferent 
lymphatic vessels. Propulsive lymph velocities and contraction frequencies ranged from 2.11 
± 0.74 to 8.13 ± 2.96 mm/s and 1.35 to 6.32/min, respectively, in 6 nude mice. 
In addition to the difference in lymphatic function between inguinal afferent and efferent 
lymphatic vessels, we also observed differences in lymphatic contractility along the lymphatic 
vessel. 
As shown in Fig. 2B, an analysis of fluorescent intensity versus time and length along the 
entire efferent lymphatic vessel shows (i) four contraction waves starting propagations 
approximately at ROI 30 and (ii) the different patterns of lymphatic propulsion, which are 
likely mediated by the different lymphangions in which the ROI’s were selected. In order to 
elucidate the different modes of lymphatic contraction and relaxation, four ROIs (i.e. ROIs 5, 
18, 30, and 66) were selected and fluorescent intensities within each ROI were plotted as a 
function of time as shown in Fig. 2C. Fluorescent intensity profiles in ROI 5 and ROI 18 
illustrate no propulsive flow and a slightly pulsatile flow, respectively. 
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Fig. 2. A 3-D plot of fluorescent intensity as a function of time and distance (B) after selecting 
66 ROIs along the lymphatic vessel (A) shows propagating contraction waves in an orthograde 
direction (arrow). (C) Plot of fluorescent intensity profiles for four ROIs showing different 
patterns of propagating contraction waves in a collecting lymphatic vessel of a nude mouse. 
Asterisk denotes ILN and broken arrow ALN. 
 
Fig. 3. Overlay of white light and fluorescent images acquired by in vivo (A) and intravital (B) 
NIR fluorescent imaging after injection of ICG and a color image (C) after injection of EBD to 
a nude mouse. Asterisk denotes ILN. Arrows in A-C denote collecting lymphatic vessels. 
Scale: 1 mm. 
Figure 2C also shows the rapid dynamic decrease of fluorescent intensities due to the 
lymphatic contraction and the subsequent slow increase in the intensities due to the lymphatic 
relaxation and lymph “filling” within ROI 30. In addition, the passage of a packet of ICG-
laden lymph through ROI 66 to the ALN is represented by intensity peaks as shown in Fig. 
2C, reflecting the contractile assembly upstream emptying (contraction) and the subsequent 
downstream filling (relaxation). We observed the propagation velocity of 8.13 ± 2.96 mm/s 
between ROIs 30 and 66. 
Intravital fluorescence imaging was also conducted after a midline incision of the 
abdominal skin from the inguinal to the axillary regions to confirm that ICG was picked up by 
the initial lymphatics and drained to LNs through the contractile, collecting lymphatic vessels. 
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trafficking of ICG along the branched internodal collecting lymphatic vessels. Figure 3B 
shows magnified images in the circle shown in Fig. 3A. As shown in Fig. 3B, the collecting 
lymphatic vessels run parallel to the blood vessels. After intravital fluorescence imaging, 10 
μL of EBD was intradermally injected at the base of the tail, but several millimeters away 
from the previous ICG injection site for direct visualization of the lymphatics. Similar to ICG, 
EBD also binds to tissue macromolecules and is selectively taken up by the initial lymphatic 
vessels [21]. Figure 3C shows the lymphatic drainage of EBD along the lymphatic vessels, 
which is the same lymphatic flow pathway depicted by ICG fluorescence in Fig. 3B. As 
demonstrated in Fig. 3, non-invasive whole-body fluorescence imaging data correlated with 
intravital fluorescence and EBD images, demonstrating that both ICG and EBD were taken up 
by the initial lymphatics and drained from the ILN, through the contractile collecting 
lymphatic vessels, to the ALN. 
 
Fig. 4. Overlay (A) of white light and fluorescent images in a C57BL/6 mouse and a 3-D plot 
of the fluorescent intensity as a function of time and distance (B) showing the propagation of 
the fluorescent packet of lymph represented by the peak in fluorescence intensity (arrow). 
Asterisk denotes ILN. 
 
Fig. 5. Overlay of white light and fluorescent images in Prox1+/ mice depicting abnormal 
lymphatic drainage patterns. 
More importantly, propulsive flow acquired from in vivo fluorescence imaging occurs 
along the lymphatic vessels. 
Figure 4 is an example from a C57BL/6 mouse, the background common to most 
transgenic mouse models. Figure 4 shows similar lymphatic architecture and function as 
described in nude mice. We observed the propagation velocity of 8.06 ± 0.74 mm/s in the 
inguinal efferent collecting lymphatic vessel. Propulsive lymph velocities and contraction 
frequencies ranged from 2.33 ± 0.51 to 8.06 ± 0.74 mm/s and 1.66 to 4.34/min, respectively, 
in 6 C57BL/6 mice. 
We also imaged PROX1+/ mice using dynamic NIR fluorescent imaging following i.d. 
injection of ICG. It has been observed that most PROX1+/ adult mice were obese compared  
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Fig. 6. Overlay (A) of white light and fluorescent images (B, Media 2) and quantification of 
abnormal lymphatic contractile function of Prox1+/ mice. Double arrows denote a tortuous 
collecting lymphatic vessel. (C) A 3-D plot of the fluorescent intensity as a function of time 
and distance. Arrow in C denotes orthograde propagating contraction wave, whereas broken 
arrow denotes retrograde propagating contraction wave. (D) Plot of fluorescent intensity 
profiles for four ROIs from which the distance between the ROIs and the transit time (Δt1 and 
Δt2) are obtained. 
with their wild-type counterparts [3]. Figure 5 shows abnormal lymphatic drainage patterns 
from the injection site on the base of the tail. Diffused dye patterns as well as tortuous and 
ruptured lymphatic vessels were visualized as shown in Fig. 5. This phenomenon was also 
reported using an invasive method with injection of EBD [3]. However, lymphatic contractile 
function in Prox1+/ mice has not been investigated. 
From our dynamic fluorescence imaging, we observed abnormal lymphatic contractile 
function as shown in Media 2. Figure 6A shows another example of overlay of white light and 
fluorescent images (Fig. 6B) from Media 2 depicting a tortuous fluorescent collecting 
lymphatic vessel indicated by a double arrow. A 3-D spatio-temporal map of fluorescent 
intensities in an inguinal efferent collecting lymphatic vessel indicates orthograde (arrow) and 
retrograde (broken arrow) propagation of contraction waves as shown in Fig. 6C. To quantify 
propagation velocity, four ROIs were selected. As shown in Fig. 6D, if we define Δt1 and Δt2 
as the time delays between the fluorescence maxima or the onset of contraction of upstream 
and downstream regions of interest (i.e. Δt1 = tpeak(ROI 30) - tpeak(ROI 1) and Δt2 = tpeak(ROI 
91) - tpeak(ROI 40)), we find negative values of Δt1 over the entire period of imaging, 
indicating that the contractions in ROI 30 preceded those in upstream ROI 1. The averaged 
Δt1 is 1.74 ± 0.16 s and the propagation velocity in the retrograde direction was found to be 
6.56 ± 0.6 mm/s. We also observed positive values of Δt2, indicating propagation of 
contraction waves in the orthograde direction. 
The averaged Δt2 is 2.81 ± 0.09 s and the propagation velocity in the orthograde direction 
was found to be 5.82 ± 0.2 mm/s. Persistent retrograde lymph flow, taken together with 
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Prox1 haploinsufficiency. Using isolated and cannulated lymphatics, investigators have 
demonstrated contractile propagation in the orthograde and retrograde directions [22–24]. 
Dixon et al. [25] showed from intravital microscopic imaging that retrograde flow occurred in 
rat mesenteric lymphatics ranging from 2 to 18% of the time during imaging procedures. We 
observed the asymmetric contractility at junctions of branched lymphatic vessels and 
retrograde propagation of contractions in normal mice using ICG fluorescence (not shown) 
similar to that reported using invasive methods by others [23,24,26,27]. 
4. Conclusion 
The physiological and pathophysiological importance of the lymphatic system could be 
characterized with non-invasive dynamic NIR fluorescence imaging. Indeed, we successfully 
demonstrated our ability to non-invasively and quantitatively image lymphatic architecture 
and contractile function in immunocompetent mice and in an animal model of lymphatic 
disease. While PROX1 mutations have not been identified in human disease, the use of non-
invasive imaging to assess lymphatic function in mouse models of disease and to compare 
with human NIR fluorescence imaging could provide a clinically relevant diagnostic of 
lymphatic function, similar to how CT and MR angiography is employed in order to assess 
contribution of the blood vasculature in a variety of human diseases. Indeed, our group is 
currently conducting whole exome sequencing in humans to identify mutations that could be 
causative for specific lymphatic phenotypes. The use of transgenic animal models to match 
the imaging phenotypes found in humans with similar genetic defects could facilitate 
identification of disease causing mutations. In addition, if these genetic mutations point to 
specific pathways that could be pharmacologically mediated, then new therapeutics could be 
discovered for lymphedema. In addition, the ability to use the technique to conduct 
longitudinal imaging may enable assessment of the response to pharmacological agents as 
well as provide new insights into lymphatic biology. 
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